Series B Raise 2/5/2020 Vena Medical is providing physicians with - PowerPoint PPT Presentation

Series B Raise 2/5/2020 “Vena Medical is providing physicians with the world’s smallest camera capable of going inside veins and arteries to help them treat stroke.”

Beachhead Market: Ischemic Stroke 01 795,000 Strokes Annually in the US • 15 million worldwide ular Acce Vasc 02 ss $34B Cost to the Healthcare System • Split between intervention and rehab 03 87% Ischemic Stroke • Clot blocks blood flow to the brain

Current Pain points Clot Buster - 3 hour time frame Harmful after 3 hours • 8% of stroke victims • • Does not treat underlying plaque Stent Retriever - 16 hour time frame 25.1%-50% first pass success rate • • $5k-$8k per device Visual confirmation necessary • • Trial and Error, Iterative Aspiration - 16 hour time frame • 25.1%-50% first pass success rate • Can cause residual clots when treating red clots • Trial and Error, Iterative https://www.ncbi.nlm.nih.gov/pubmed/29459390

3

Vena Microcatheter “the imaging catheter” Vena MicroAngioscope ™ “the imaging catheter”

Vena MicroAngioscope • Visual confirmation of • Physician preference and • Generic 5 minute rule • 18% of cases cause residual best guess retrieval clots Status Quo: • First pass success of 25.1%- • Expensive escalation • Contrast from X-ray 50% algorithms pushes clots further • Misdiagnosed atherosclerotic plaque Vascular Verify Confirm Check Identify the Position Retrieval Work Access Best T ool • Aspiration better for white • We can identify and • Real-time deployment • Real-time confirmation of clots remove these residual clots retrieval • Verify apposition Vena: • Stentriever better for red • We can confirm the clot • 8 strokes treated with clots has been removed before 100% first pass success • Different stentrievers for they go on to block smaller different clot compositions arteries

Market Overview 01 240,000 Potential Patient Population • Annual US Patient Population ular Acce Vasc 02 $5000 & Single-use ss • Piece price per system, saving hospitals $3500 per procedure 03 $1,200,000,000 Annually • Estimated Revenue at 100% Market Share

Traction Raised our Series A Round November 2019 Moved into the Medical Innovation Xchange August 2019 First conference presentation at WLNC May 2019 FDA Pre-Submission Meeting April 2019 First publication in JNIS January 2019 First full-time hire, Director of QA September 2018 Broad stroke treatment Dr. Kan invests patent filed July 2018 January 2019 First thrombectomy animal study at Baylor Completed MassChallenge T exas June 2018 August 2018 Maria Aboytes comes on board April 2018 Completed Y Combinator Completed TMCx March 2018 November 2017 First animal study First patent filed October 2017 August 2017

IP Portfolio The portfolio covers the system as a whole, the optical fiber, the microcatheter, and the balloon catheter individually.

Path T o Market $1.5M HC First in Man $1M $0.5M V&VT esting 25-50 Paid Cases $650k Second Submission First Submission QMS and Product Dev Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021 Q3 2021 Seed <$1M Series A <$10M Series B <$20M

OUR TEAM Michael PHILLIPS Phil COOPER Brandon CARHART Dr. Hanna QIN Dr. Peter KAN Founder Founder Director of QA R&D Scientist Chief of Neuro-endovascular Service Dr. Steven COOPER Maria ABOYTES Tasha BOND Allison KOMIYAMA Primary Medical Advisor Advisor / Medina Medical / Technical Advisor / Former Regulatory Specialist Inventor of FlowGate Vention Medical 10

We’ve successfully treated stroke in a pig model using our latest prototype We have an extremely straight forward path to market We have prominent physicians backing our product and helping us develop it Secured an investment to fund through to commercialization “Making intravascular procedures faster, easier and safer”

Waterloo, Ontario +1-506-434-1388 Michael@VenaMed.ca www.venamed.ca